

Prostate Cancer Drugs-Europe Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/P18C98330F0MEN.html>

Date: February 2018

Pages: 148

Price: US\$ 3,480.00 (Single User License)

ID: P18C98330F0MEN

Abstracts

Report Summary

Prostate Cancer Drugs-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Prostate Cancer Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Prostate Cancer Drugs 2013-2017, and development forecast 2018-2023

Main market players of Prostate Cancer Drugs in Europe, with company and product introduction, position in the Prostate Cancer Drugs market

Market status and development trend of Prostate Cancer Drugs by types and applications

Cost and profit status of Prostate Cancer Drugs, and marketing status

Market growth drivers and challenges

The report segments the Europe Prostate Cancer Drugs market as:

Europe Prostate Cancer Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Germany

United Kingdom

France

Italy

Spain

Benelux

Russia

Europe Prostate Cancer Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Hormonal Therapy

Chemotherapy

Immunotherapy

Targeted Therapy

Europe Prostate Cancer Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Clinics

Hospitals

Other

Europe Prostate Cancer Drugs Market: Players Segment Analysis (Company and Product introduction, Prostate Cancer Drugs Sales Volume, Revenue, Price and Gross Margin):

AbbVie

Astellas Pharma

Astra Zeneca

Johnson & Johnson

Sanofi

GlaxoSmithKline

Merck Group

Novartis

Amgen

Bayer HealthCare

Ferring Pharmaceutical

Janssen Pharmaceuticals

Endo Pharmaceuticals

BMS

Takeda Pharmaceuticals

Northwest Biotherapeutics

Teva Pharmaceutical
Boehringer Ingelheim
Foresee Pharmaceuticals
Tokai Pharmaceuticals
Spectrum Pharmaceuticals

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF PROSTATE CANCER DRUGS

- 1.1 Definition of Prostate Cancer Drugs in This Report
- 1.2 Commercial Types of Prostate Cancer Drugs
 - 1.2.1 Hormonal Therapy
 - 1.2.2 Chemotherapy
 - 1.2.3 Immunotherapy
 - 1.2.4 Targeted Therapy
- 1.3 Downstream Application of Prostate Cancer Drugs
 - 1.3.1 Clinics
 - 1.3.2 Hospitals
 - 1.3.3 Other
- 1.4 Development History of Prostate Cancer Drugs
- 1.5 Market Status and Trend of Prostate Cancer Drugs 2013-2023
 - 1.5.1 Europe Prostate Cancer Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Prostate Cancer Drugs Market Status and Trend 2013-2023

CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Prostate Cancer Drugs in Europe 2013-2017
- 2.2 Consumption Market of Prostate Cancer Drugs in Europe by Regions
 - 2.2.1 Consumption Volume of Prostate Cancer Drugs in Europe by Regions
 - 2.2.2 Revenue of Prostate Cancer Drugs in Europe by Regions
- 2.3 Market Analysis of Prostate Cancer Drugs in Europe by Regions
 - 2.3.1 Market Analysis of Prostate Cancer Drugs in Germany 2013-2017
 - 2.3.2 Market Analysis of Prostate Cancer Drugs in United Kingdom 2013-2017
 - 2.3.3 Market Analysis of Prostate Cancer Drugs in France 2013-2017
 - 2.3.4 Market Analysis of Prostate Cancer Drugs in Italy 2013-2017
 - 2.3.5 Market Analysis of Prostate Cancer Drugs in Spain 2013-2017
 - 2.3.6 Market Analysis of Prostate Cancer Drugs in Benelux 2013-2017
 - 2.3.7 Market Analysis of Prostate Cancer Drugs in Russia 2013-2017
- 2.4 Market Development Forecast of Prostate Cancer Drugs in Europe 2018-2023
 - 2.4.1 Market Development Forecast of Prostate Cancer Drugs in Europe 2018-2023
 - 2.4.2 Market Development Forecast of Prostate Cancer Drugs by Regions 2018-2023

CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole Europe Market Status by Types
 - 3.1.1 Consumption Volume of Prostate Cancer Drugs in Europe by Types
 - 3.1.2 Revenue of Prostate Cancer Drugs in Europe by Types
- 3.2 Europe Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in Germany
 - 3.2.2 Market Status by Types in United Kingdom
 - 3.2.3 Market Status by Types in France
 - 3.2.4 Market Status by Types in Italy
 - 3.2.5 Market Status by Types in Spain
 - 3.2.6 Market Status by Types in Benelux
 - 3.2.7 Market Status by Types in Russia
- 3.3 Market Forecast of Prostate Cancer Drugs in Europe by Types

CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Prostate Cancer Drugs in Europe by Downstream Industry
- 4.2 Demand Volume of Prostate Cancer Drugs by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Prostate Cancer Drugs by Downstream Industry in Germany
 - 4.2.2 Demand Volume of Prostate Cancer Drugs by Downstream Industry in United Kingdom
 - 4.2.3 Demand Volume of Prostate Cancer Drugs by Downstream Industry in France
 - 4.2.4 Demand Volume of Prostate Cancer Drugs by Downstream Industry in Italy
 - 4.2.5 Demand Volume of Prostate Cancer Drugs by Downstream Industry in Spain
 - 4.2.6 Demand Volume of Prostate Cancer Drugs by Downstream Industry in Benelux
 - 4.2.7 Demand Volume of Prostate Cancer Drugs by Downstream Industry in Russia
- 4.3 Market Forecast of Prostate Cancer Drugs in Europe by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF PROSTATE CANCER DRUGS

- 5.1 Europe Economy Situation and Trend Overview
- 5.2 Prostate Cancer Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 PROSTATE CANCER DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE

- 6.1 Sales Volume of Prostate Cancer Drugs in Europe by Major Players

6.2 Revenue of Prostate Cancer Drugs in Europe by Major Players

6.3 Basic Information of Prostate Cancer Drugs by Major Players

6.3.1 Headquarters Location and Established Time of Prostate Cancer Drugs Major Players

6.3.2 Employees and Revenue Level of Prostate Cancer Drugs Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 PROSTATE CANCER DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 AbbVie

7.1.1 Company profile

7.1.2 Representative Prostate Cancer Drugs Product

7.1.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of AbbVie

7.2 Astellas Pharma

7.2.1 Company profile

7.2.2 Representative Prostate Cancer Drugs Product

7.2.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Astellas Pharma

7.3 Astra Zeneca

7.3.1 Company profile

7.3.2 Representative Prostate Cancer Drugs Product

7.3.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Astra Zeneca

7.4 Johnson & Johnson

7.4.1 Company profile

7.4.2 Representative Prostate Cancer Drugs Product

7.4.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson

7.5 Sanofi

7.5.1 Company profile

7.5.2 Representative Prostate Cancer Drugs Product

7.5.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Sanofi

7.6 GlaxoSmithKline

7.6.1 Company profile

7.6.2 Representative Prostate Cancer Drugs Product

7.6.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of

GlaxoSmithKline

7.7 Merck Group

7.7.1 Company profile

7.7.2 Representative Prostate Cancer Drugs Product

7.7.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Merck Group

7.8 Novartis

7.8.1 Company profile

7.8.2 Representative Prostate Cancer Drugs Product

7.8.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Novartis

7.9 Amgen

7.9.1 Company profile

7.9.2 Representative Prostate Cancer Drugs Product

7.9.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Amgen

7.10 Bayer HealthCare

7.10.1 Company profile

7.10.2 Representative Prostate Cancer Drugs Product

7.10.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Bayer HealthCare

HealthCare

7.11 Ferring Pharmaceutical

7.11.1 Company profile

7.11.2 Representative Prostate Cancer Drugs Product

7.11.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Ferring

Pharmaceutical

7.12 Janssen Pharmaceuticals

7.12.1 Company profile

7.12.2 Representative Prostate Cancer Drugs Product

7.12.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Janssen

Pharmaceuticals

7.13 Endo Pharmaceuticals

7.13.1 Company profile

7.13.2 Representative Prostate Cancer Drugs Product

7.13.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Endo

Pharmaceuticals

7.14 BMS

7.14.1 Company profile

7.14.2 Representative Prostate Cancer Drugs Product

7.14.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of BMS

7.15 Takeda Pharmaceuticals

7.15.1 Company profile

- 7.15.2 Representative Prostate Cancer Drugs Product
- 7.15.3 Prostate Cancer Drugs Sales, Revenue, Price and Gross Margin of Takeda Pharmaceuticals
- 7.16 Northwest Biotherapeutics
- 7.17 Teva Pharmaceutical
- 7.18 Boehringer Ingelheim
- 7.19 Foresee Pharmaceuticals
- 7.20 Tokai Pharmaceuticals
- 7.21 Spectrum Pharmaceuticals

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PROSTATE CANCER DRUGS

- 8.1 Industry Chain of Prostate Cancer Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF PROSTATE CANCER DRUGS

- 9.1 Cost Structure Analysis of Prostate Cancer Drugs
- 9.2 Raw Materials Cost Analysis of Prostate Cancer Drugs
- 9.3 Labor Cost Analysis of Prostate Cancer Drugs
- 9.4 Manufacturing Expenses Analysis of Prostate Cancer Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF PROSTATE CANCER DRUGS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Prostate Cancer Drugs-Europe Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/P18C98330F0MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P18C98330F0MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970